ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Company has presented a poster showcasing the Parsortix®system at the American Association for Cancer Research Conference (AACR) 2022, held in New Orleans, United States on 8-13 April 2022.
The research presented related to the use of the Parsortix system with triple negative breast cancer (TNBC) patients. TNBC is a form of invasive breast cancer, which has limited treatment choices and a poor prognosis.
The poster attracted industry interest as it demonstrated the ability to analyse cancer cells harvested from patient blood samples, known as circulating tumour cells (CTCs), for key markers of interest and, as a result of its capability to investigate both mesenchymal and epithelial CTCs, a significantly higher positivity rate than alternative approaches. Key features included the high proportion of CTCs of mesenchymal phenotype and the high proportion of patient samples with CTC clusters, both of which are key differentiating factors of the Parsortix system.
ANGLE is offering this workflow as part of its pharma services business for longitudinal monitoring of patients in cancer drug trials.
The poster is available online at https://angleplc.com/library/publications/#posters.